[1] [1] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CAA Cancer J Clin, 2022, 72(1): 7-33.

[2] [2] THRIFT A P, WENKER T N, EL-SERAG H B. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention[J]. Nat Rev Clin Oncol, 2023, 20(5): 338-349.

[3] [3] HAN B F, ZHENG R S, ZENG H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.

[5] [5] JOSHI S S, BADGWELL B D. Current treatment and recent progress in gastric cancer[J]. CA Cancer J Clin, 2021, 71(3): 264-279.

[6] [6] CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.

[7] [7] LIU J H, YUAN Q H, GUO H, et al. Deciphering drug resistance in gastric cancer: Potential mechanisms and future perspectives[J]. Biomed Pharmacother, 2024, 173: 116310.

[8] [8] ZHAO Y, LI S R, ZHU L F, et al. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer[J]. Cell Rep Med, 2024, 5(7): 101627.

[9] [9] ROSSI M, ALTEA-MANZANO P, DEMICCO M, et al. PHGDH heterogeneity potentiates cancer cell dissemination and metastasis[J]. Nature, 2022, 605(7911): 747-753.

[10] [10] DONG J K, LEI H M, LIANG Q, et al. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase[J]. Theranostics, 2018, 8(7): 1808-1823.

[11] [11] SHEN L L, ZHANG J F, ZHENG Z T, et al. PHGDH inhibits ferroptosis and promotes malignant progression by upregulating SLC7A11 in bladder cancer[J]. Int J Biol Sci, 2022, 18(14): 5459-5474.

[12] [12] WANG K, LUO L, FU S Y, et al. PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma[J]. Nat Commun, 2023, 14(1): 1011.

[13] [13] KUZUOGLU-OZTURK D. PHGDH and cancer: new job for an old enzyme![J]. EMBO J, 2023, 42(3): e113068.

[14] [14] WANG K X, LU H, WANG X M, et al. Simultaneous suppression of PKM2 and PHGDH elicits synergistic anti-cancer effect in NSCLC[J]. Front Pharmacol, 2023, 14: 1200538.

[15] [15] CHEN C, ZHU T Y, LIU X Q, et al. Identification of a novel PHGDH covalent inhibitor by chemical proteomics and phenotypic profiling[J]. Acta Pharm Sin B, 2022, 12(1): 246-261.

[16] [16] LUO L, WU X Y, FAN J W, et al. FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma[J]. Nat Commun, 2024, 15(1): 4790.

[17] [17] WEI L, LEE D, LAW C T, et al. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC[J]. Nat Commun, 2019, 10(1): 4681.

[18] [18] ZHANG C, YU J J, YANG C, et al. Wild-type IDH1 maintains NSCLC sternness and chemoresistance through activation of the serine biosynthetic pathway[J]. Sci Transl Med, 2023, 15(726): eade4113.

[19] [19] ZHANG X C, SUN M G, JIAO Y S, et al. PHGDH inhibitor CBR-5884 inhibits epithelial ovarian cancer progressionviaROS/wnt/-catenin pathway and plays a synergistic role with PARP inhibitor olaparib[J]. Oxid Med Cell Longev, 2022, 2022: 9029544.

[20] [20] JIN L, KIANG K M, CHENG S Y, et al. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma[J]. Lab Invest, 2022, 102(2): 194-203.

[21] [21] HWANG Y, YUN H J, JEONG J W, et al. Co-inhibition of glutaminolysis and one-carbon metabolism promotes ROS accumulation leading to enhancement of chemotherapeutic efficacy in anaplastic thyearoid cancer[J]. Cell Death Dis, 2023, 14(8): 515.

[22] [22] XIAN Y, ZHANG S, WANG X D, et al. Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer[J]. Onco Targets Ther, 2016, 9: 5553-5560.

[23] [23] ZHANG H, KONG W M, ZHAO X L, et al. Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma[J]. BMC Med Genomics, 2023, 16(1): 29.

[24] [24] SONG Z W, FENG C, LU Y L, et al. PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer[J]. Gene, 2018, 642: 43-50.

[25] [25] DUAN X X, CHEN Y H, ZHANG K, et al. PHGDH promotes esophageal squamous cell carcinoma progressionviaWnt/-catenin pathway[J]. Cell Signal, 2023, 109: 110736.

[26] [26] ZHANG D, LI A M, HU G H, et al. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy[J]. Cell Metab, 2023, 35(3): 517-534. e8.